PT Indofarma Tbk (ISX:INAF) ROCE % : -72.23% (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is PT Indofarma Tbk ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PT Indofarma Tbk's annualized ROCE % for the quarter that ended in Sep. 2023 was -72.23%.

PT Indofarma Tbk ROCE % Historical Data

The historical data trend for PT Indofarma Tbk's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Indofarma Tbk ROCE % Chart

PT Indofarma Tbk Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

3.61

5.97

6.19

5.61

-63.28

PT Indofarma Tbk Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-39.39	-185.95	-40.58	-49.48	-72.23

PT Indofarma Tbk ROCE % Calculation

PT Indofarma Tbk's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-479476.871	/	( ( (2011879.396 - 1045188.438)	+	(1534000.447 - 985245.941) )	/ 2 )
	=	-479476.871	/	( (966690.958	+	548754.506)	/ 2 )
	=	-479476.871	/	757722.732
	=	-63.28 %

PT Indofarma Tbk's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-268190.812	/	( ( (1559064.75 - 1151004.523)	+	(1491062.01 - 1156470.213) )	/ 2 )
	=	-268190.812	/	( ( 408060.227	+	334591.797 )	/ 2 )
	=	-268190.812	/	371326.012
	=	-72.23 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

PT Indofarma Tbk (ISX:INAF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PT Indofarma Tbk ROCE % Related Terms

Thank you for viewing the detailed overview of PT Indofarma Tbk's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PT Indofarma Tbk (ISX:INAF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530

Website

http://www.indofarma.id

PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.

PT Indofarma Tbk (ISX:INAF) Headlines

No Headlines